Using the protirelin test to distinguish mania from schizophrenia

Area of Science:

• Neuroendocrinology
• Psychiatry

Background:

• Differentiating between manic and schizophrenic disorders presents clinical challenges.
• Thyroid-stimulating hormone (TSH) response to thyrotropin-releasing hormone (TRH) has been investigated as a potential biomarker.

Purpose of the Study:

• To evaluate the diagnostic utility of the protirelin (TRH) test in distinguishing between manic and schizophrenic patients.
• To assess the thyroid-stimulating hormone (TSH) response to protirelin in patients with mania, schizophrenia, and healthy controls.

Main Methods:

• Administered a test dose of protirelin to 30 euthyroid inpatients with mania, 30 with schizophrenia (undifferentiated subtype), and 20 healthy controls.
• Measured the maximal change in thyroid-stimulating hormone (TSH) response (delta TSH) following protirelin administration.
• Analyzed differences in delta TSH, considering factors like age, sex, baseline thyroid function, cortisol, and medication.

Main Results:

• Manic patients exhibited a significantly lower mean maximal TSH response (delta TSH) compared to schizophrenic patients and controls.
• This difference was independent of age, sex, baseline thyroid status, cortisol levels, or medication.
• A delta TSH cutoff of ≤7.0 µIU/mL demonstrated 60% sensitivity and 84% specificity for identifying manic patients within the study cohort.

Conclusions:

• The protirelin test shows potential as an adjunctive tool for differentiating manic from schizophrenic patients.
• While overlap exists, specific TSH response patterns may aid in differential diagnosis.
• Further research is warranted to validate the protirelin test's clinical applicability in psychiatric diagnosis.